{"search_session":{},"preferences":{"l":"en","queryLanguage":"en"},"patentId":"US_8211631_B2","frontPageModel":{"patentViewModel":{"ref":{"entityRefType":"PATENT","entityRefId":"112-586-699-396-864"},"entityMetadata":{"linkedIds":{"empty":true},"tags":[],"collections":[{"id":8892,"type":"PATENT","title":"University of Wisconsin Patent Portfolio","description":"","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":15082,"tags":[],"user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"notes":[{"id":8214,"type":"COLLECTION","user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"text":"
Search Applicants and Owners = \"Wisconsin University\" , \"University of Wisconsin\", \"Wisconsin Univ\", \" Univ Wisconsin\" , \"Wisco* Alum* Res* Found*\".
Select more for logical variants
Add to collection
Search Applicants and Owners = \"Wisconsin University\" , \"University of Wisconsin\", \"Wisconsin Univ\", \" Univ Wisconsin\" , \"Wisco* Alum* Res* Found*\".
Select more for logical variants
Add to collection
(a) obtaining a population of induced pluripotent stem (iPS) cells derived from somatic cells from a spinal muscular atrophy (SMA) patient;\n
(b) culturing the cells of step (a) into neurons that maintain an SMA disease genotype and phenotype either before or after exposure to a test compound; and\n
(c) examining the effect of the test compound on SMN protein levels, wherein a modification in SMN protein levels in cells exposed to the test compound relative to SMN protein levels in cells that have not been exposed to the test compound indicates that the compound modifies cellular SMN protein levels."],"number":1,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1 wherein the exposure to the test compound occurs after the step of culturing the cells into neurons of step (b), and wherein the neurons have an SMN protein level similar (+/−10%) to the SMN protein level of neurons of a spinal muscular atrophy patient."],"number":2,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1 wherein step (c) is via examination of nuclear gem localization."],"number":3,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 2 wherein step (c) is via examination of nuclear gem localization."],"number":4,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1 wherein the somatic cells are fibroblasts."],"number":5,"annotation":false,"title":false,"claim":true},{"lines":["A method of evaluating compounds as an SMA therapy comprising the steps of\n
(a) obtaining a population of induced pluripotent stem (iPS) cells derived from somatic cells from a spinal muscular atrophy (SMA) patient;\n
(b) culturing the cells of step (a) into a cell population comprising motor neurons that maintain an SMA disease genotype and phenotype either before or after exposure to a test compound; and\n
(c) examining the effect of the test compound on the survival of motor neurons generated in step (b), wherein the increased survival of motor neurons that have been exposed to the test compound or the increased survival of motor neurons derived from cells exposed to the test compound relative to the survival of motor neurons that have not been exposed to the test compound or motor neurons derived from cells that have not been exposed to the test compound indicates that the compound is a candidate for SMA therapy."],"number":6,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 6 wherein the exposure to the test compound occurs after the step of culturing the cells into neurons of step (b), and wherein the neurons have an SMN protein level similar (+/−10%) to the SMN protein level of neurons of a spinal muscular atrophy patient."],"number":7,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 2 wherein the somatic cells are fibroblasts."],"number":8,"annotation":false,"title":false,"claim":true}]}},"filters":{"npl":[],"notNpl":[],"applicant":[],"notApplicant":[],"inventor":[],"notInventor":[],"owner":[],"notOwner":[],"tags":[],"dates":[],"types":[],"notTypes":[],"j":[],"notJ":[],"fj":[],"notFj":[],"classIpcr":[],"notClassIpcr":[],"classNat":[],"notClassNat":[],"classCpc":[],"notClassCpc":[],"so":[],"notSo":[],"sat":[]},"sequenceFilters":{"s":"SEQIDNO","d":"ASCENDING","p":0,"n":10,"sp":[],"si":[],"len":[],"t":[],"loc":[]}}